Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders

Background: Individuals with substance use disorders (SUDs) are at increased risk for hepatitis C viral infection (HCV), and few studies have explored their treatment responses empirically. The objective of this study was to assess interferon alpha therapy (IFN) completion and response rates among patients with HCV who had a history of comorbid SUDs. More data is needed to inform treatment strategies and guidelines for these patients. Using a medical record database, information was retrospectively collected on 307,437 veterans seen in the Veterans Integrated Service Network 20 (VISN 20) of the Veterans Healthcare Administration (VHA) between 1998 and 2003. For patients treated with any type of IFN (including regular or pegylated IFN) or combination therapy (IFN and ribavirin) who had a known HCV genotype, IFN completion and response rates were compared among patients with a history of SUD (SUD+ Group) and patients without a history of SUD (SUD-Group).

[1]  E. Bini,et al.  Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. , 2006, Gastroenterology.

[2]  L. Cheever,et al.  Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Sylvestre.  Treating hepatitis C virus infection in active substance users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Lepage,et al.  Is the management of hepatitis C patients appropriate? A population‐based study , 2005, Alimentary pharmacology & therapeutics.

[5]  R. Weber,et al.  Interferon alpha-2a Plus Ribavirin 1,000/1,200 mg versus Interferon alpha-2a Plus Ribavirin 600 mg for Chronic Hepatitis C Infection in Patients on Opiate Maintenance Treatment: An Open-Label Randomized Multicenter Trial , 2005, Infection.

[6]  P. Hauser,et al.  The phenomenology and treatment of interferon-induced depression. , 2004, Journal of affective disorders.

[7]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[8]  P. Thuras,et al.  A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. , 2003, Psychosomatics.

[9]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[10]  L. Sidoli,et al.  Alcohol abstinence does not offset the strong negative effect of lifetime alcohol consumption on the outcome of interferon therapy , 2002, Journal of viral hepatitis.

[11]  D. Sylvestre.  Treating hepatitis C in methadone maintenance patients: an interim analysis. , 2002, Drug and alcohol dependence.

[12]  D. Provenzale,et al.  A Descriptive Evaluation of Eligibility for Therapy Among Veterans With Chronic Hepatitis C Virus Infection , 2002, Journal of clinical gastroenterology.

[13]  K. Bjøro,et al.  Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up , 2002, European Addiction Research.

[14]  B. Luxon,et al.  Limited success of HCV antiviral therapy in United States veterans , 2002, American Journal of Gastroenterology.

[15]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[16]  G. Davis,et al.  Treatment of chronic hepatitis C in active drug users. , 2001, The New England journal of medicine.

[17]  K. Seal,et al.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? , 2001, The New England journal of medicine.

[18]  M. Backmund,et al.  Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.

[19]  J. Stephenson.  Former addicts face barriers to treatment for HCV. , 2001, JAMA.

[20]  Huy A. Nguyen,et al.  Influence of psychiatric diagnoses on interferon-α treatment for chronic hepatitis C in a veteran population , 2001, American Journal of Gastroenterology.

[21]  S. Tortu,et al.  HEPATITIS C AMONG NONINJECTING DRUG USERS: A REPORT , 2001, Substance use & misuse.

[22]  J. Buxton,et al.  Public Health and Hepatitis C , 2000, Canadian Journal of Public Health.

[23]  M. D. Di Marino,et al.  Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. , 2000, Alcohol and alcoholism.

[24]  K. Fujiwara,et al.  Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. , 1996, The American journal of gastroenterology.

[25]  H. Yoshihara,et al.  Efficacy of interferon therapy in patients with chronic hepatitis C. Comparison between non-drinkers and drinkers. , 1994, Scandinavian journal of gastroenterology.

[26]  S. Padosch,et al.  Substance Abuse Treatment, Prevention, and Policy , 2006 .

[27]  F. Buntinx,et al.  Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU) : guidelines for clinical practice. , 2005, Acta gastro-enterologica Belgica.

[28]  S. Dinwiddie,et al.  Prevalence of hepatitis C among psychiatric patients in the public sector. , 2003, The American journal of psychiatry.

[29]  C. Howell,et al.  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C , 2002, Molecular Psychiatry.

[30]  M. Malaguarnera,et al.  Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.